Rovida Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Rovida Advisors’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,155,004	Closed	-$22.8M	–	52
2019 Q4	$22.8M	Buy	+1,155,004	New	+$22.1M	1.21%	30

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rovida Advisors's TAK Position: Q1 2020 in Review

Rovida Advisors sold out of Takeda Pharmaceutical (TAK) in Q1 2020, closing a stake of 1,155,004 shares — an estimated $22.8M sold.

Rovida Advisors first reported a position in TAK in Q4 2019 and held it in 1 quarter. The position peaked at $22.8M in Q4 2019. 312 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

Rovida Advisors reported no remaining Takeda Pharmaceutical position as of Q1 2020 after selling out during the quarter.
Rovida Advisors sold 1,155,004 Takeda Pharmaceutical shares in Q1 2020, an estimated $22.8M.
Rovida Advisors first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 1 quarter.
Rovida Advisors's Takeda Pharmaceutical position peaked at $22.8M in Q4 2019.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on Rovida Advisors's 13F filing for Q1 2020, filed 13 May 2020.